VNDA Vanda Pharmaceuticals Inc.

14.05
+0.00  (0%)
Previous Close 14.05
Open 14.30
Price To book 4.88
Market Cap 625.96M
Shares 44,552,000
Volume 440,081
Short Ratio 3.61
Av. Daily Volume 492,250

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2017.
Tradipitant
Gastroparesis
PK trial initiated with data due 2018.
HETLIOZ (tasimelteon)
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data due in 2H 2017.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 2 data due in mid-2017.
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis

Latest News

  1. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017
  2. ETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017
  3. Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT
  4. Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer
  5. Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
  6. Vanda reports 1Q loss
  7. Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results
  8. Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call
  9. Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
  10. Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 20, 2017
  11. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April 19, 2017
  12. Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
  13. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017
  14. Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors
  15. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017
  16. Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences
  17. Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
  18. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : February 21, 2017
  19. Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT